Tele: 561.316.3330
Breaking Medical Device News

Wednesday, September 22, 2021
HomeEXECUTIVESDonald J. Jones, a Digital Therapeutics Expert Joins the BODs of Theranica

Donald J. Jones, a Digital Therapeutics Expert Joins the BODs of Theranica

January 19, 2021

Donald J. Jones is a digital therapeutics expert who has joined the board of directors of Theranica.

Donald J. Jones said, “I am honored by the opportunity to join Theranica’s board and am excited to contribute to the success of Nerivio.”  “Theranica is uniquely positioned to advance the non-pharmacological pain therapy industry. Nerivio is an innovative treatment for migraine, a condition that plagues too many people. I look forward to working closely with the talented management team and other board members to drive the company forward and further expand the US customer base.”

Donald J. Jones has spent more than 35 years developing, founding, growing, and scaling national and international healthcare enterprises, such as MedTrans, EMME, HealthCap, and others. For over a decade Mr. Jones served as Qualcomm’s Vice President and founded Qualcomm’s digital health subsidiary. He serves as Chief Digital Officer at Scripps Research Translational Institute, and as an independent board member for venture capital and private equity-backed health companies and on Fortune 1000 Digital Health Advisory Boards, and is globally recognized for his digital transformation expertise.

“Mr. Jones brings complementary knowhow and experience in growing and scaling digital therapeutics companies, and we’re thrilled to collaborate with him to make a national and global impact in the health-tech market,” said Theranica Co-founder and CEO, Alon Ironi. “He joins us at an exciting time, as demand for Nerivio continues to grow and we serve more and more people suffering from migraine. We welcome him and are thrilled to work together with him.”

Theranica’s FDA-cleared prescribed migraine therapeutic wearable Nerivio®, is worn on the upper arm and utilizes Remote Electrical Neuromodulation, controlled from a smartphone, to activate the brain’s native Conditioned Pain Modulation mechanism to treat pain and associated migraine symptoms.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy